Integrated PTSD and Chronic Pain Treatment

Last updated: December 15, 2025
Sponsor: Weill Medical College of Cornell University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Chronic Pain

Post-traumatic Stress Disorders

Pain

Treatment

Integrated Treatment for PTSD and Chronic Pain

Clinical Study ID

NCT07225049
25-01028464
  • Ages > 18
  • All Genders

Study Summary

Posttraumatic stress disorder (PTSD) occurs in approximately 7% of adults in the general population. PTSD greatly impacts quality of life and often co-occurs with other conditions such as chronic pain. Individuals with co-morbid PTSD and chronic pain demonstrate higher PTSD symptoms and pain (as well as greater anxiety, depression, disability, and opioid use) compared to those with only one of those conditions. Gold standard treatments exist for both PTSD (e.g., Prolonged Exposure; PE) and chronic pain (e.g., Cognitive Behavioral Therapy for Chronic Pain; CBT-CP) and are generally offered sequentially (i.e., one at a time for the condition that is most prominent). Treating these conditions separately may overlook their interconnected nature, which may reduce efficacy and increase dropout. Thus, there is a need for an intervention to target both simultaneously, which may be more effective and efficient than treating conditions sequentially.

This is a single-arm pilot study to assess the feasibility and acceptability of an integrated treatment for adults with comorbid PTSD and chronic pain. The intervention consists of 12 90-minute virtual psychotherapy sessions scheduled twice per week. The treatment draws from modules in PE and CBT-CP including psychoeducation, exposure to feared/avoided situations and activities, processing of exposures, behavioral activation, breathing and relaxation techniques, sleep hygiene, symptom monitoring, and structured homework assignments. Baseline and post-treatment assessments will be conducted.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years or older

  • English-speaking

  • Currently meets criteria for PTSD, assessed by the CAPS-5 (any trauma type) -Chronic pain, assessed by greater than or equal to 4 on a scale of 0-10 painseverity over the past 3 months

  • Medically stable at the time of study enrollment (chronic illness and disabilitydoes not prevent attendance of outpatient therapy sessions)

  • Stable on psychotropic medication for past 60 days

  • Agreed to not change current medication or pain-related treatments over the courseof the study unless medically necessary

Exclusion

Exclusion Criteria:

  • Lifetime diagnosis of schizophrenia, other psychotic disorder, or bipolar I disorder

  • Participation in concurrent evidence-based psychological treatment for PTSD orchronic pain during the past 3 months

  • Participants must not participate in an evidence-based psychological treatment foreither PTSD or pain during the course of the study.

  • Moderate or severe substance use in the past 90 days

  • Cognitive impairment to the degree that the patient cannot provide informed consentor fill out assessment measures

  • Participants who in the PI's judgement pose a current homicidal or suicidal risk

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: Integrated Treatment for PTSD and Chronic Pain
Phase:
Study Start date:
December 08, 2025
Estimated Completion Date:
August 31, 2027

Connect with a study center

  • Weill Cornell Medicine

    New York 5128581, New York 5128638 10065
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.